Stock 1177 SINO BIOPHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Sino Biopharmaceutical Limited

Equities

1177

KYG8167W1380

Delayed Hong Kong S.E.
Other stock markets
 10:10:28 2024-07-04 pm EDT 		5-day change 1st Jan Change
2.75 HKD +0.73% Intraday chart for Sino Biopharmaceutical Limited +3.00% -20.75%
Jun. 25 Sino Biopharmaceutical Gets NMPA's Nod for Marketing Diabetes Drug MT
Jun. 25 Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sino Biopharmaceutical Gets NMPA's Nod for Marketing Diabetes Drug
MT
Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection
CI
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Yuan in Panda Bonds
MT
Sino Biopharmaceutical Completes Issuance of 1.5 Billion Panda Bonds
MT
Sino Biopharmaceutical Gets Marketing Go-Ahead for Lung Cancer Drug in China
MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"
CI
Sino Biopharm Trustee Purchases 15.8 Million Shares Under Incentive Scheme
MT
Sino Biopharmaceutical Gets Marketing Go-Ahead for MRI Contrast Agent from Chinese Regulator
MT
Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection
CI
Sino Biopharmaceutical's Phase 2 Trial Results of Lung Cancer Tablet Published in Medical Journal
MT
Sino Biopharmaceutical Limited Announces Publication of Study Findings of Phase II Clinical Trial of KRAS G12C Inhibitor "Garsorasib (D-1553) in the Lancet Respiratory Medicine
CI
Sino Biopharmaceutical Limited Announces KRAS G12C Inhibitor Garsorasib Tablet (D-1553) Included in the Breakthrough Therapeutic Designation Process
CI
Final dividend
FA
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
RE
Sino Biopharmaceutical Presents Findings of Anti-Tumor Drug at American Cancer Conference
MT
Sino Biopharmaceutical Cuts Conversion Price of Euro-Denominated Bonds Due 2025
MT
Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director
CI
Sino Biopharmaceutical's Renal Cancer Combination Treatment Shows Promise in Phase III Trials
MT
Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma
CI
Sino Biopharmaceutical's Novel Lung Cancer Drug Approved in China; Shares Up 5%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1177 Stock
  4. News Sino Biopharmaceutical Limited